Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Survival following HIV infection of a cohort followed up from seroconversion in the UK.

Ewings FM, Bhaskaran K, McLean K, Hawkins D, Fisher M, Fidler S, Gilson R, Nock D, Brettle R, Johnson M, Phillips A, Porter K; UK Register of HIV Seroconverters.

AIDS. 2008 Jan 2;22(1):89-95.

PMID:
18090396
2.

[Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].

Pezzotti P, Dorrucci M, Donisi A, Cusini M, Mazzarello G, De Luca A, Salassa B, Ursitti MA, Giuliani M, Rezza G; l'Italian Seroconversion Study.

Epidemiol Prev. 2003 Nov-Dec;27(6):348-55. Italian.

PMID:
15058363
3.

Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE.

CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) Collaboration.

HIV Med. 2000 Oct;1(4):224-31.

4.

Determinants of survival following HIV-1 seroconversion after the introduction of HAART.

Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Porter K, Walker AS; CASCADE Collaboration.

Lancet. 2003 Oct 18;362(9392):1267-74.

PMID:
14575971
5.

Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category.

Pérez-Hoyos S, del Amo J, Muga R, del Romero J, García de Olalla P, Guerrero R, Hernàndez-Aguado I; GEMES (Spanish Multicenter Study Group of Seroconverters).

AIDS. 2003 Feb 14;17(3):353-9.

PMID:
12556689
7.

Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study.

Dorrucci M, Pezzotti P, Phillips AN, Alliegro MB, Rezza G.

AIDS. 1997 Mar 15;11(4):461-7.

PMID:
9084793
8.

Changes in the risk of death after HIV seroconversion compared with mortality in the general population.

Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, Porter K; CASCADE Collaboration.

JAMA. 2008 Jul 2;300(1):51-9. doi: 10.1001/jama.300.1.51.

PMID:
18594040
9.

Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999.

del Amo J, del Romero J, Barrasa A, Pérez-Hoyos S, Rodríguez C, Díez M, García S, Soriano V, Castilla J; Grupo de Seroconvertores de la Comunidad de Madrid.

Sex Transm Infect. 2002 Aug;78(4):255-60.

10.

Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.

Detels R, Muñoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrager LK, Phair JP.

JAMA. 1998 Nov 4;280(17):1497-503.

PMID:
9809730
11.

Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.

Bhaskaran K, Mussini C, Antinori A, Walker AS, Dorrucci M, Sabin C, Phillips A, Porter K; CASCADE Collaboration.

Ann Neurol. 2008 Feb;63(2):213-21.

PMID:
17894380
12.

The risk of AIDS-defining events is decreasing over time in the German HIV-1 Seroconverter Cohort.

Altmann M, An der Heiden M, Scheufele R, Hartmann K, Houareau C, Bartmeyer B, Hamouda O; German HIV-1 Seroconverter Cohort.

BMC Infect Dis. 2012 Apr 19;12:94. doi: 10.1186/1471-2334-12-94.

13.

HIV seroincidence and correlates of seroconversion in a cohort of male factory workers in Harare, Zimbabwe.

Mbizvo MT, Machekano R, McFarland W, Ray S, Bassett M, Latif A, Katzenstein D.

AIDS. 1996 Jul;10(8):895-901.

PMID:
8828747
14.

Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART.

Muga R, Ferreros I, Langohr K, de Olalla PG, Del Romero J, Quintana M, Alastrue I, Belda J, Tor J, Pérez-Hoyos S, Del Amo J; Spanish Multicenter Study Group of Seroconverters (GEMES).

AIDS. 2007 Nov 30;21(18):2521-7.

PMID:
18025889
15.
16.

Survival of HIV-infected treatment-naive individuals with documented dates of seroconversion in Rakai, Uganda.

Lutalo T, Gray RH, Wawer M, Sewankambo N, Serwadda D, Laeyendecker O, Kiwanuka N, Nalugoda F, Kigozi G, Ndyanabo A, Bwanika JB, Reynolds SJ, Quinn T, Opendi P.

AIDS. 2007 Nov;21 Suppl 6:S15-9. doi: 10.1097/01.aids.0000299406.44775.de.

PMID:
18032934
17.

Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001.

García de la Hera M, Ferreros I, del Amo J, García de Olalla P, Pérez Hoyos S, Muga R, del Romero J, Guerrero R, Hernández-Aguado I; GEMES.

J Epidemiol Community Health. 2004 Nov;58(11):944-50.

19.

Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy.

Todd J, Glynn JR, Marston M, Lutalo T, Biraro S, Mwita W, Suriyanon V, Rangsin R, Nelson KE, Sonnenberg P, Fitzgerald D, Karita E, Zaba B.

AIDS. 2007 Nov;21 Suppl 6:S55-63. doi: 10.1097/01.aids.0000299411.75269.e8.

PMID:
18032940
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk